mRCC-话题@MedSci - 梅斯（MedSci）

#mRCC#

7篇内容 | 1094人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1755625, encodeId=2ad41e55625c6, content=<a href='/topic/show?id=9bc112192fd' target=_blank style='color:#2F92EE;'>#mRCC#</a>, objectTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, objectType=article, longId=219184, objectId=9df12191846b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9df12191846b, replyNumber=0, likeNumber=74, createdTime=2021-11-30, rootId=0, userName=刘阔, userId=c36036973392, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9df12191846b, moduleTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9df12191846b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755622, encodeId=67621e55622da, content=<a href='/topic/show?id=9bc112192fd' target=_blank style='color:#2F92EE;'>#mRCC#</a>, objectTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, objectType=article, longId=215476, objectId=dc262154e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc262154e628, replyNumber=0, likeNumber=70, createdTime=2022-04-19, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc262154e628, moduleTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dc262154e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755624, encodeId=9bd71e5562451, content=<a href='/topic/show?id=9bc112192fd' target=_blank style='color:#2F92EE;'>#mRCC#</a>, objectTitle=The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效, objectType=article, longId=219179, objectId=3d182191e9b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d182191e9b7, replyNumber=0, likeNumber=124, createdTime=2022-03-07, rootId=0, userName=刘阔, userId=c36036973392, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d182191e9b7, moduleTitle=The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3d182191e9b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755623, encodeId=19c51e5562373, content=<a href='/topic/show?id=9bc112192fd' target=_blank style='color:#2F92EE;'>#mRCC#</a>, objectTitle=Eur Urol：立体定向放疗可改善接受TKI治疗的寡进展性mRCC患者的治疗效果, objectType=article, longId=216261, objectId=ba64216261c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba64216261c5, replyNumber=0, likeNumber=88, createdTime=2022-03-13, rootId=0, userName=刘阔, userId=c36036973392, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba64216261c5, moduleTitle=Eur Urol：立体定向放疗可改善接受TKI治疗的寡进展性mRCC患者的治疗效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ba64216261c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755621, encodeId=74d71e55621db, content=<a href='/topic/show?id=9bc112192fd' target=_blank style='color:#2F92EE;'>#mRCC#</a>, objectTitle=Oncologist：贝伐单抗+伊沙匹隆治疗mRCC还可以走多远？, objectType=article, longId=105586, objectId=e908105586ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e908105586ed, replyNumber=0, likeNumber=68, createdTime=2017-07-20, rootId=0, userName=刘阔, userId=c36036973392, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e908105586ed, moduleTitle=Oncologist：贝伐单抗+伊沙匹隆治疗mRCC还可以走多远？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e908105586ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755620, encodeId=8df71e556200c, content=<a href='/topic/show?id=9bc112192fd' target=_blank style='color:#2F92EE;'>#mRCC#</a>, objectTitle=JCO：卡博替尼对比舒尼替尼作为mRCC患者初始靶向治疗的差异与风险评估(Alliance A031203 CABOSUN 试验), objectType=article, longId=82815, objectId=ec4a8281505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec4a8281505, replyNumber=0, likeNumber=97, createdTime=2017-01-22, rootId=0, userName=刘阔, userId=c36036973392, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec4a8281505, moduleTitle=JCO：卡博替尼对比舒尼替尼作为mRCC患者初始靶向治疗的差异与风险评估(Alliance A031203 CABOSUN 试验), moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ec4a8281505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755619, encodeId=624f1e556199b, content=<a href='/topic/show?id=9bc112192fd' target=_blank style='color:#2F92EE;'>#mRCC#</a>, objectTitle=BJUI：肿瘤负荷可作为mRCC的独立预后指标, objectType=article, longId=11944, objectId=257111944eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=257111944eb, replyNumber=0, likeNumber=85, createdTime=2013-02-27, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=257111944eb, moduleTitle=BJUI：肿瘤负荷可作为mRCC的独立预后指标, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=257111944eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mRCC

2020-05-29

刘阔 (审核中...)

前往app查看评论内容

#mRCC#

The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响

2021-11-30

爆笑小医 (审核中...)

前往app查看评论内容

#mRCC#

Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效

2022-04-19

刘阔 (审核中...)

前往app查看评论内容

#mRCC#

The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效

2022-03-07

刘阔 (审核中...)

前往app查看评论内容

#mRCC#

Eur Urol：立体定向放疗可改善接受TKI治疗的寡进展性mRCC患者的治疗效果

2022-03-13

刘阔 (审核中...)

前往app查看评论内容

#mRCC#

Oncologist：贝伐单抗+伊沙匹隆治疗mRCC还可以走多远？

2017-07-20

刘阔 (审核中...)

前往app查看评论内容

#mRCC#

JCO：卡博替尼对比舒尼替尼作为mRCC患者初始靶向治疗的差异与风险评估(Alliance A031203 CABOSUN 试验)

2017-01-22

docwu2019 (审核中...)

前往app查看评论内容

#mRCC#

BJUI：肿瘤负荷可作为mRCC的独立预后指标

2013-02-27

科室
- - 订阅+
  - 更多科室
工具
服务